Recent 8-K filings for BIXT
Highest-materiality recent filing
Bioxytran reports Phase 2 ProLectin-M shows 100% viral clearance at day 7; p=0.001
- 100% of treated subjects achieved complete viral clearance by Day 7 vs placebo (p=.001).
- No viral rebounds observed during the 14-day post-treatment observation period.
-
Bioxytran completes $1.2M private placement, issues 21.1M shares and 19.8M warrants
Gross proceeds of approximately $1.2 million from sale of 21,071,667 shares at $0.055 per share.
-
Bioxytran amends preferred stock conversion rights, grants CEO 6M preferred shares
Amendment requires both Board and majority of Preferred holders to approve any conversion of Convertible Preferred Stock into common shares.
-
Bioxytran's ProLectin-M achieves 90% Day-5 viral clearance in Phase 1b/2a COVID-19 study
Phase 1b/2a trial: 39 patients; highest dose 16,800 mg/day showed 90% Day-5 viral clearance vs 20% placebo (p=0.001).
-
Bioxytran signs distribution deal with Khoury Medical for A-SUQAR supplement
Agreement with Khoury Medical to commercialize A-SUQAR, a chewable blood sugar supplement using Bioxytran's PHGG formulation.
-
Bioxytran reports Phase 2 ProLectin-M shows 100% viral clearance at day 7; p=0.001
100% of treated subjects achieved complete viral clearance by Day 7 vs placebo (p=.001).
-
Bioxytran terminates Officer Mike Sheikh; Sheikh contests dismissal reason affecting severance
Mike Sheikh terminated as an Officer effective December 29, 2025.
-
Director resigns citing governance concerns; Bioxytran hires independent expert for controls review
Anders Utter resigns from Bioxytran's Board and Audit Committee chair, effective Dec 7, 2025, citing need for enhanced oversight and controls.
-
Bioxytran acquires NDPD Pharma in $15.85M stock deal; CFO adopts 10b5-1 plan
Acquired 100% of NDPD Pharma for 3,389,169 common shares and 28,467,564 preferred shares valued at ~$12.46M.
-
Bioxytran secures $1.6M stock purchase with Triton Funds; management forfeits $460K salaries
Triton Funds LP commits up to $1.6M for up to 17.5M shares (19.9%) at lowest traded price 10 days prior to closing.
-
BioXytran restates 2022-2023 financials on share valuation errors; non-reliance on prior filings
Net loss for 2023 increased by $192,523 to $4.56M; for 2022 increased by $9,202 to $2.67M.
-
Bioxytran publishes preprint on galectin-3's role in ICI resistance and potential enhancement
Preprint reviews theories that galectin-3 contributes to ICI resistance; galectin-3 antagonists may reverse effect.
-
Bioxytran acquires NDPD Pharma for $15.85M in stock; CFO adopts 10b5-1 plan
Acquired 100% of NDPD Pharma for stock: 3.39M common shares at $0.109 and 28.47M preferred shares at $0.543.
-
Bioxytran issues 28.97M preferred shares to insiders, converts 94M common shares and $354K debt
Issued 28,971,248 convertible preferred shares to insiders in exchange for 94,057,658 common shares at a 5:1 ratio.
-
Bioxytran launches JV with Heme Foundation for universal oxygen carrier; up to $10M pledged
JV with Heme Foundation and NDPD Pharma to develop Universal Oxygen Carrier (UOC) as blood substitute.
-
Bioxytran announces Springer book linking hyperbaric oxygenation to BXT-25 drug
Book by Prof. Mayevsky published by Springer; covers hyperbaric oxygenation and mitochondrial activity.
-
Bioxytran dismisses BF Borgers, appoints Fruci & Associates as new auditor
Dismissed BF Borgers CPA PC as independent auditor effective May 7, 2024.
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material